DUBLIN--(BUSINESS WIRE)--The "Genomic Cancer Panel and Profiling Markets 2025-2029 by Cancer, Application, Tissue, and Gene Type with Screening Potential Market Size, Featuring Executive & Consultant Guides" report has been added to ResearchAndMarkets.com's offering.
The report serves as a vital resource for analysts and planners, offering extensive data to guide strategic decisions. It comprises detailed information, including a comprehensive compilation of United States Medicare Fee Payment Schedules, which elucidates new pricing structures for cancer panels.
Planners can forecast demand for novel testing methodologies or technologies and make more informed research investment decisions. For existing laboratories and hospitals, the report aids in forecasting and planning for the growth of clinical facilities, with ongoing support readily available to maximize the utility of the provided information.
The realm of Cancer Gene Panels and Genomic Profiling is experiencing a paradigm shift in cancer diagnosis and treatment, with Artificial Intelligence propelling the industry into mainstream medical practice. Oncologists are increasingly leveraging information from hundreds of cancer-related genes, positioning the market on a trajectory of explosive growth within two distinct segments. This transformation heralds a new era where cancer diagnostics are on the brink of revolution.
In a rapidly evolving market landscape, comprehensive panels and genomic profiling are becoming pivotal. High-risk breast cancer panels illustrate how industry players are strategically positioning themselves, with some expanding their reach on a global scale. The dynamic nature of this market presents substantial opportunities where diagnostics combined with robust support can secure premium pricing. As scientific advancements continue and sequencing costs decrease, new opportunities for innovation consistently emerge.
The report meticulously details breakouts for 18 countries across 4 regions, offering an invaluable tool for stakeholders aiming to understand the granularities of market dynamics. Purchasers can also access detailed breakouts for any specific country upon request, broadening the perspective on a global scale.
This comprehensive report encapsulates the potential of AI in redefining cancer diagnostics through gene panels and genomic profiling. As the market capitalizes on scientific advancements and decreasing sequencing costs, the opportunities for growth and innovation in cancer treatment are boundless. This report is an essential guide for those seeking to navigate and thrive in this burgeoning market.
Key Topics Covered:
1 Market Guides
1.1 Cancer Panel Market - Strategic Situation Analysis
1.2 Large Comprehensive Cancer Panel Market - Situation Analysis
1.3 Guide for Executives, Marketing, Sales and Business Development Staff
1.4 Guide for Management Consultants and Investment Advisors
1.5 Impact of Artificial Intelligence on Cancer Profiling Market
2 Introduction and Market Definition
2.1 What are Cancer Gene Panels and Profiling?
2.2 The Sequencing Revolution
2.3 Market Definition
2.4 Methodology
2.5 Perspective: Healthcare Spending
3 Market Overview
3.1 Players in a Dynamic Market
3.2 Oncogenomics
3.3 Cancer Management vs. Diagnosis
3.4 Phases of Adoption - Looking into The Future
3.5 Structure of Industry Plays a Part
3.6 Currently Available Large Comprehensive Assays
3.7 Pricing Profiling vs. Whole Exome (or Genome) Sequencing
4 Market Trends
4.1 Factors Driving Growth
4.1.1 Level of Care
4.1.2 Companion Dx
4.1.3 Immuno-oncology
4.1.4 Liability
4.1.5 The Aging Effect
4.2 Factors Limiting Growth
4.2.1 State of knowledge
4.2.2 Genetic Blizzard
4.2.3 Protocol Resistance
4.2.4 Regulation and coverage
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 Bioinformatics Plays a Role
4.4 Diagnostic Technology Development
4.4.1 Next Generation Sequencing Fuels a Revolution
4.4.2 Single Cell Genomics Changes the Picture
4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
4.4.4 CGES Testing, A Brave New World
4.4.5 Biochips/Giant magneto resistance based assay
5 Cancer Panels & Profiles Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 Foundation Medicine, Fulgent Genetics to Launch Germline Testing
5.3 Advanced Genomics APAC, 3BIGS Partner on Cancer Testing
5.4 Lucence Assay Gets Coverage for Advanced Solid Tumors
5.5 Foundation Medicine, AnHeart Therapeutics to Develop CDx for NSCLC Therapy
5.6 Roche CGP Assay Shows Concordance With Other NGS-Based Assays
5.7 Precede Biosciences Emerges From Stealth With $57M
5.8 Geneseeq Nabs CE Marks for Cancer Test Kits
5.9 Realm IDx Profiling Test Gets National Health Coverage in Japan
5.10 Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics
5.11 Guardant Health Secures Coverage for Liquid Biopsy Profiling Test
5.12 Myriad Genetics, Intermountain Precision Genomics Obtain NY Certification for Tumor Profiling
5.13 Cota, Genomic Testing Coop Ink Oncology Partnership
5.14 Euformatics, ViennaLab, Oncompass Win Liquid Biopsy Development Contract
5.15 Prenetics' Cancer Profiling Test Receives FDA Clearance
5.16 Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy
5.17 Thermo Fisher Introduces Homologous Score for Cancer Profiling
5.18 Genomic Test IDs Cancer Cells Early
5.19 Caris Life Sciences to Offer Molecular Profiling Services
5.20 Geneseeq to Build Lab for Cancer Profiling in Brazil
5.21 Genetron Health Adds New Assays to Pipeline
5.22 Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay
5.23 Guardant Health Receives Medicare Coverage for Guardant360 TissueNextT Test
5.24 Cancer Screening Launch Approaches, Guardant Health Plans New Comprehensive Assay
5.25 Thermo Fisher, Oncocyte Ink Deal for Cancer IVDs
5.26 Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role
5.27 Labcorp, CCORN Partner for Precision Oncology
5.28 Dante Labs Acquires Cambridge Cancer Genomics
5.29 Celemics, Strand Partner on Integrated Platform for NGS Analysis
5.30 Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries
5.31 Burning Rock Revenues Rise
5.32 Caris Life Sciences to Expand Liquid Biopsy Testing
5.33 OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence
5.34 Intermountain and Myriad Combine Test Offering
5.35 Illumina, Geneseeq to Offer Cancer Testing Kits in China
5.36 Exact Sciences to Offer End-to-End Cancer Testing
5.37 Guardant Health Turns to Tumor Tissue Sequencing
5.38 Tempus Inks Oncology Testing Collaboration With Bayer
5.39 Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
5.40 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
5.41 Metastatic Cancer Markers Identified in Clinical WGS Study
5.42 Stitch Bio Bets on CRISPR Tech
5.43 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
5.44 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
5.45 Progress, Challenges in Liquid Biopsy Reimbursement
5.46 Israeli Startup Curesponse Raises $6M
5.47 Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
5.48 MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
5.49 NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
5.50 Germline Results Guides Precision Therapy in Advanced Cancer
5.51 FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
5.52 ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
5.53 Labs Reporting Cancer Risk Mutations from Tumor Testing
5.54 Users Begin Integrating Genomics Data for Clinical Decision Support
5.55 Fujitsu Improves Efficiency in Cancer Genomic Medicine
6 Profiles of Key Players
6.1 10x Genomics, Inc.
6.2 Abbott Laboratories
6.3 AccuraGen Inc.
6.4 Adaptive Biotechnologies
6.5 Admera Health, LLC
6.6 Aethlon Medical
6.7 Agilent
6.8 Amoy Diagnostics Co., Ltd.
6.9 Anchor Dx
6.10 ANGLE plc
6.11 ARUP Laboratories
6.12 AVIVA Systems Biology
6.13 Baylor Miraca Genetics Laboratories
6.14 Beckman Coulter Diagnostics (Danaher)
6.15 Becton, Dickinson and Company
6.16 BGI Genomics Co. Ltd.
6.17 Bioarray Genetics
6.18 Biocartis
6.19 Biocept, Inc.
6.20 Biodesix Inc.
6.21 BioFluidica
6.22 BioGenex
6.23 BioIVT
6.24 Biolidics Ltd
6.25 bioMerieux Diagnostics
6.26 Bioneer Corporation
6.27 Bio-Rad Laboratories, Inc
6.28 Bio-Reference Laboratories
6.29 Bio-Techne
6.30 Bioview
6.31 Bristol-Myers Squibb
6.32 Burning Rock
6.33 C2i Genomics
6.34 Cardiff Oncology
6.35 Caris Molecular Diagnostics
6.36 Castle Biosciences, Inc.
6.37 Celemics
6.38 CellMax Life
6.39 Cepheid (Danaher)
6.40 Charles River Laboratories
6.41 Circulogene
6.42 Clearbridge Biomedics
6.43 Clinical Genomics
6.44 Cytolumina Technologies Corp.
6.45 Datar Cancer Genetics Limited
6.46 Diagnologix LLC
6.47 Diasorin S.p.A.
6.48 Element Biosciences
6.49 Enzo Biochem
6.50 Epic Sciences
6.51 Epigenomics AG
6.52 Eurofins Scientific
6.53 Exact Sciences
6.54 Fabric Genomics
6.55 Fluxion Biosciences (Cell Microsystems)
6.56 Freenome
6.57 FUJIFILM Wako Diagnostics
6.58 Fujirebio
6.59 GeneDx Holdings
6.60 GeneFirst Ltd.
6.61 Genetic Technologies Ltd.
6.62 Genetron Holdings
6.63 GenomOncology
6.64 GILUPI Nanomedizin
6.65 Guardant Health
6.66 HansaBiomed
6.67 HTG Molecular Diagnostics
6.68 iCellate
6.69 ICON PLC
6.70 Illumina
6.71 Incell Dx
6.72 Inivata
6.73 Invitae Corporation
6.74 Invivogen
6.75 Invivoscribe
6.76 J&J Innovative Medicine
6.77 KEW
6.78 Lucence Health
6.79 Lunglife AI Inc
6.80 MDNA Life SCIENCES, Inc.
6.81 MDx Health
6.82 Menarini Silicon Biosystems
6.83 Mesa Laboratories, Inc.
6.84 Millipore Sigma
6.85 Miltenyi Biotec
6.86 miR Scientific
6.87 Myriad Genetics
6.88 Nanostring
6.89 NantHealth, Inc.
6.90 Natera
6.91 NeoGenomics
6.92 NGeneBio
6.93 Novogene
6.94 Oncimmune
6.95 Oncocyte
6.96 OncoDNA
6.97 OraLiva
6.98 Oxford Nanopore Technologies
6.99 Panagene
6.100 Personalis
6.101 Perthera
6.102 PGDx (Labcorp)
6.103 Precipio
6.104 PrecisionMed
6.105 Predictive Oncology
6.106 Prenetics
6.107 Promega
6.108 Qiagen
6.109 QuidelOrtho
6.110 Rarecells SAS
6.111 RareCyte
6.112 Revvity
6.113 Roche Diagnostics
6.114 Screencell
6.115 Sherlock Biosciences
6.116 Siemens Healthineers
6.117 simfo GmbH
6.118 Singlera Genomics Inc.
6.119 Singular Genomics
6.120 Singulomics
6.121 SkylineDx
6.122 Standard BioTools
6.123 Stilla Technologies
6.124 Sysmex Inostics
6.125 Tempus Labs, Inc.
6.126 Thermo Fisher Scientific
6.127 Todos Medical
6.128 Ultima Genomics
6.129 Variantyx
6.130 Vela Diagnostics
6.131 Veracyte
6.132 VolitionRX
6.133 Vortex Biosciences
For more information about this report visit https://www.researchandmarkets.com/r/91k4ft
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
